Anti-PD-1 administration may improve the prognosis of patients characterized by both tumor cells’ PD-L1 expression and TILs, as shown by multiple studies.31, 32 PD-L1 expression on tumor cells and immune-infiltrating cells, such as tumor-infiltrating macrophages, appears to be a crucial predictor of the antitumor T cells’ response. This evidence concerns the gene CD274 and neoplasm.